Blogs

A new resource from the National Alliance of Healthcare Purchaser Coalitions aims to help plan sponsors adopt biosimilars into their pharmacy benefit plans. View Full Article on The Center for Biosimilars

From the publisher of this report : In this report, we analyze the perspectives of more than 350 providers in the therapeutic areas with the most potential for disruption in the year ahead:rheumatology, gastroenterology, dermatology and ophthalmology. Combined with perspectives from leading experts, we give a view of the industry and the imminent market shift that will come from competition with Humira™ and biosimilar utilization. We also analyze the latest industry data on utilization, government pricing reform, and payer coverage. View Report

From the publisher of this report : Amgen’s 2022 Biosimilar Trends Report is a point-in-time overview of key trends in the US biosimilars marketplace, and it is intended to be a resource to help stakeholders better understand the current and future state of the biosimilars marketplace, and key considerations related to the evolving biosimilars landscape. The information provided in this report is for background and informational purposes only and is not intended to promote Amgen’s products or any other products. View Report

This report from the National Alliance of Healthcare Purchasers offers insights and a framework for employers on how they can better influence how drugs are managed on their behalf. Read More The National Alliance created an infographic in tandem with the report above. Click on the link below to view the infographic, including the recommended action steps employers can take to regain control over prescription drug benefit management. Infographic – Employer RX Value Assessment: Building the Bridges to Sustainability

Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help reduce total biologic drug spend. While they have not driven down costs as had been expected, biosimilar uptake amongst employers and PBMs has been slow. Read More

A small, yet rapidly growing segment of commercially insured US patients have drug costs of more than $250,000 each year, and this group could account for 15% of all drug expenditures in the next 5 years. Read more .

Advancement in the treatment of a wide variety of cancers has resulted from significant innovations in the pharmaceutical pipeline. These developments present significant challenges to payers due to the high costs associated with them. Read more .

The problem of drug pricing is not the brainchild of a Pharma cabal of Dr. Evils. The problem is a cabal of public policies virtually everyone in America supports. Read More

Action steps employers can take to influence change that will ultimately lead to more options for employees and their dependents who are dealing with diseases like cancer, rheumatoid arthritis and others. From the National Alliance of Healthcare Purchaser Coalitions (NAHPC). Read more .

Employers only have a minimal understanding of their current pharmacy benefit manager contracts. Read full article here .

The insurance giant is leaving its current PBM in 2020, and if it can accomplish better transparency and lower prices, the savings could potentially be seen by employers as well. Read the full article here .